Previous study has reported that oral administration of NNAV could inhibit the protein levels of P-IKK-α, recover IκB-α levels, and prevent the translocation of NF-κB to the nucleus in the rat model of nephropathy [18]. Here, NFKB1 is linked to kidney disorder.